Date: 2016-05-11
Type of information: Licensing agreement
Compound:
Company: The Lead Discovery Center (LDC) (Germany) Max Planck Innovation (Germany) Boehringer Ingelheim (Germany)
Therapeutic area: CNS diseases - Mental diseases
Type agreement: licensing
Action mechanism:
Disease: schizophrenia
Details: * On May 11, 2016, The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH and Boehringer Ingelheim have signed an agreement providing Boehringer Ingelheim with the option to receive the exclusive rights to a new lead compound for the treatment of schizophrenia to be discovered and developed at the LDC. The novel approach builds on ground-breaking research results from Prof. Moritz Rossner and his team at the Max Planck Institute of Experimental Medicine in Göttingen. He will work closely together with the LDC team to identify and optimize novel compounds with strong therapeutic potential and develop it further to the stage of a validated pharmaceutical lead with in vivo efficacy. Moritz Rossner holds also a Professorship at Ludwig Maximilians University, Munich and is a co-founder of Systasy Bioscience GmbH.
Financial terms: In this early discovery project Boehringer Ingelheim will take a seat on the project development team and will pay an option fee. In addition, the company will allocate internal resources to the programand support collaborating partners to strengthen the early development work. Once the project has attained proof-of-concept in relevant invivo models Boehringer Ingelheim can exclusively license the lead at pre-defined terms for subsequent preclinical and clinical development. Any revenue the LDC may receive from commercialization will be shared with the academic inventors and collaborating institutions.
Latest news:
